Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TriSalus Life SciencesTLSI -0.81%29 3-Year EBITDA Growth Rate is 82.10% as of Mar. 2026, which is 3% above its 10-year median of 79.60. GuruFocus rates TLSI with a GF Score™ of 29/100 and a GF Value™ of $4.30 (Fairly Valued). The stock has 5 warning signs investors should review. Among 692 Medical Devices & Instruments companies, TriSalus Life Sciences ranks better than 96.68% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 82.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of TriSalus Life Sciences was 82.10% per year. The lowest was 77.10% per year. And the median was 79.60% per year.
TriSalus Life Sciences (NAS:TLSI) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
TriSalus Life Sciences 3-Year EBITDA Growth Rate Related Terms
TLSI vs TMCI, LAB, SENS: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, TriSalus Life Sciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's 3-Year EBITDA Growth Rate falls into.
TriSalus Life Sciences 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 82.10% mean?
TriSalus Life Sciences (TLSI) has a 3-Year EBITDA Growth Rate of 82.10% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for TriSalus Life Sciences and its competitors. This is near median its historical median of 79.60. Over the past decade, TriSalus Life Sciences' 3-Year EBITDA Growth Rate has ranged from 77.10 to 82.10. According to the industry distribution chart, TriSalus Life Sciences ranks #23 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 3.3%.
Is TriSalus Life Sciences' 3-Year EBITDA Growth Rate too high?
TriSalus Life Sciences' current 3-Year EBITDA Growth Rate of 82.10% is near median its 10-year median of 79.60. Over the past 10 years, this metric has ranged from a low of 77.10 to a high of 82.10. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.65. TriSalus Life Sciences' value of 82.10% is 973.2% above this industry median. Based on the distribution chart, TriSalus Life Sciences ranks #23 out of 692 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, TriSalus Life Sciences has a GF Score™ of 29/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' 3-Year EBITDA Growth Rate compare to TMCI and LAB?
According to the Medical Devices & Instruments industry distribution chart, TriSalus Life Sciences ranks #23 out of 692 companies for 3-Year EBITDA Growth Rate. This places TriSalus Life Sciences in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 7.65. TriSalus Life Sciences' value of 82.10% is 973.2% above this benchmark. Historically, TriSalus Life Sciences' own 3-Year EBITDA Growth Rate has ranged from 77.10 to 82.10 over the past decade. While the company's 10-year median is 79.60 vs. the industry median of 7.65, TriSalus Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.65, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TriSalus Life Sciences's current 3-Year EBITDA Growth Rate of 82.10% is 973.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for TriSalus Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TriSalus Life Sciences's current 3-Year EBITDA Growth Rate is 82.10%, which is near median its own 10-year median of 79.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Fairly Valued. The stock's GF Value™ is $4.30, compared to a current price of $4.31 — trading 0.1% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 82.10%, which is near median its 10-year median of 79.60 and 973.2% above the Medical Devices & Instruments industry median of 7.65. TriSalus Life Sciences' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current 3-Year EBITDA Growth Rate is 82.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TriSalus Life Sciences (TLSI) Overvalued in 2026?
Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be overvalued.
The current stock price of $4.31 is trading 0.1% above its estimated GF Value™ of $4.30.
GuruFocus considers TriSalus Life Sciences to be Fairly Valued.
Key valuation signals for TLSI:
3-Year EBITDA Growth Rate: 82.10% (near median its 10-year median of 79.60)
GF Value™: $4.30 vs. price of $4.31 (0.1% above fair value)
Industry Position: 973.2% above the Medical Devices & Instruments median (#23 of 692)
No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
29GF Score
Get the complete analysis for TLSI
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSI has been successfully added to your 
